

NIHR performance in initiating and delivering research: Sussex Partnership: Quarters 3 2019-2020

Data for DCR: clinical (commercial) research closed to recruitment within last 12m

	REC Number	IRAS Number	Name of Clinical Trial	Target date to recruit patients available?	Min Recruitment Target	Max Recruitment Target	Target Date to Recruit Participants available?	Date Agreed To Recruit Target Number Of Participants	Was Target Agreed	Number of participants recruited at target date	Total Number of Study Participants Recruited	Date Trial Closed to Recruitment	Reason for Closure	Date Site Initiated
Q4 2018-19	14/LO/1994	161812	A 24month,Multicenter, Randomised, Double-blind, Placebo controlled, Parallel group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease	Date Agreed	8	10	b) Date agreed	01/10/2016	Number Agreed	5	5	23/01/2019	Recruitment finished	
	17/LO/0380	218003	A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER'S DISEASE	Date Agreed	5	5	b) Date agreed	27/11/2017	Number Agreed	2	2	30/01/2019	Withdrawn by sponsor	
Q1 2019-20	N/A No commercial studies closed													
Q2 2019-20	17/WM/0146	220303	A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer's Disease	Date not agreed	5	5	Not agreed		Number Agreed	5	5	13/09/2019	Withdrawn by sponsor	
Q3 2019-20	18/EE/0151	244573	A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies (Delphia)	Date Agreed	2	6	b) date agreed	05/12/2018	Number Agreed	3	3	15/11/2019	Recruitment finished	